ID: ALA2069023

Max Phase: Preclinical

Molecular Formula: C33H48O7

Molecular Weight: 556.74

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COC(=O)CCCCCCC(=O)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](c4ccc(=O)oc4)CC[C@]32O)C1

Standard InChI:  InChI=1S/C33H48O7/c1-31-17-14-24(40-30(36)9-7-5-4-6-8-28(34)38-3)20-23(31)11-12-27-26(31)15-18-32(2)25(16-19-33(27,32)37)22-10-13-29(35)39-21-22/h10,13,21,23-27,37H,4-9,11-12,14-20H2,1-3H3/t23-,24+,25-,26+,27-,31+,32-,33+/m1/s1

Standard InChI Key:  MFFIAADGYJRDIR-HKANKZDDSA-N

Associated Targets(Human)

H(+)/Cl(-) exchange transporter 3 23 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HepG2 196354 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

CCRF S-180 1031 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

H22 575 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 556.74Molecular Weight (Monoisotopic): 556.3400AlogP: 6.31#Rotatable Bonds: 9
Polar Surface Area: 103.04Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 0.27CX LogP: 5.47CX LogD: 5.47
Aromatic Rings: 1Heavy Atoms: 40QED Weighted: 0.28Np Likeness Score: 2.01

References

1. Kamano Y, Yamashita A, Nogawa T, Morita H, Takeya K, Itokawa H, Segawa T, Yukita A, Saito K, Katsuyama M, Pettit GR..  (2002)  QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).,  45  (25): [PMID:12459012] [10.1021/jm0202066]
2. Liu J, Zhang D, Li Y, Chen W, Ruan Z, Deng L, Wang L, Tian H, Yiu A, Fan C, Luo H, Liu S, Wang Y, Xiao G, Chen L, Ye W..  (2013)  Discovery of bufadienolides as a novel class of ClC-3 chloride channel activators with antitumor activities.,  56  (14): [PMID:23799775] [10.1021/jm400881m]

Source